Therefore, a series of additional signaling studies was conducted to further define a link between CD8+ T cell activation and NLRP3 inflammasome activation in tumors, revealing tumor PD-L1-mediated triggering of NLRP3 activation via a STAT3-protein kinase R (PKR) pathway (Figure 1) [54,60,61]. This evidence concerns the gene EIF2AK2 and neoplasm.